Trav4n-3 inhibitors are a class of chemical compounds that specifically interact with the Trav4n-3 protein or receptor, inhibiting its biological function by blocking or altering its active conformation. These inhibitors typically function by binding to the active site of the Trav4n-3 protein, preventing the natural substrate or ligand from accessing it, thereby reducing its activity. Alternatively, they can bind to an allosteric site-an area of the protein distinct from the active site-which induces a conformational change that decreases the protein's functional capability. The interaction between Trav4n-3 inhibitors and the protein is mediated by various non-covalent forces such as hydrogen bonds, hydrophobic interactions, electrostatic forces, and van der Waals interactions, which together contribute to the inhibitor's specificity and stability within the protein's binding pocket.
Structurally, Trav4n-3 inhibitors are highly diverse, reflecting the complexity of the protein's active or allosteric sites. These inhibitors may range from small organic molecules to larger, more complex compounds such as peptides or macrocyclic structures. The design of these inhibitors often includes key functional groups like hydroxyl, amine, carboxyl, or halogen groups, which can form essential interactions with the target protein. Additionally, the balance of hydrophobic and hydrophilic regions within the inhibitor structure plays a crucial role in determining how effectively it binds to the Trav4n-3 protein. For instance, hydrophobic regions may enhance binding affinity through interactions with non-polar regions of the protein, while hydrophilic groups can improve solubility and interaction with polar amino acids in the protein's active or allosteric sites. The physicochemical properties of Trav4n-3 inhibitors-such as molecular weight, polarity, lipophilicity, and solubility-are important factors in optimizing their function and ensuring a stable interaction with the target protein under physiological conditions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which could inhibit the activity of Trav4n-3 by preventing its phosphorylation, a modification often critical for protein function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase inhibitor that could inhibit downstream signaling pathways that Trav4n-3 may be involved in, thereby reducing its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another phosphoinositide 3-kinase inhibitor which could inhibit signaling pathways that are necessary for the full functional activity of Trav4n-3. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which could inhibit the MAPK/ERK pathway, potentially reducing the activity of Trav4n-3 if this pathway phosphorylates or otherwise regulates Trav4n-3. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2, which could inhibit the MAPK/ERK pathway and decrease Trav4n-3 activity if Trav4n-3 is regulated by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase, which could inhibit signaling pathways necessary for the functional activity of Trav4n-3. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, which could inhibit pathways that regulate Trav4n-3 activity, thereby inhibiting Trav4n-3 indirectly. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which could lead to reduced protein synthesis and inhibit proteins that are regulated by mTOR activity, potentially including Trav4n-3. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor that could inhibit signaling pathways that involve Src family kinases, which may be necessary for Trav4n-3 activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits Bcr-Abl tyrosine kinase and could inhibit signaling pathways that Trav4n-3 may be part of, thereby inhibiting its activity. | ||||||